Chronic myeloid leukaemia (CML) can be treated sucAllogeneic bone marrow transplantation (BMT) is a successful treatment modality for patients with chronic myeloid leukaemia (CML). Sixty to 80 percent of patients cessfully with allogeneic bone marrow transplantation transplanted with unmanipulated BM in first chronic phase (BMT) leading to long-term disease-free survival. Leu-(CP) achieve long-term disease-free survival. 1 However, kemia relapse, however, remains a significant clinical relapse rates of 10-20% are still the most frequent cause problem. Relapse following BMT presumably results of treatment failure. 2,3 Leukaemia relapse following BMT from the expansion of small numbers of recipient leupresumably results from the inability of the conditioning kaemic cells which have survived the conditioning therregimen to eliminate all recipient leukaemic cells. Ideally, apy. In order to define patients who are at a high risk following BMT, the recipient's bone marrow should be of leukaemia relapse, a variety of techniques have been completely ablated by the conditioning regimen, facilitating employed to detect persistence of host haemopoiesis the engraftment of donor haemopoietic stem cells giving (mixed chimaerism, MC) or residual leukaemia rise to a complete donor haemopoietic chimaera.
7-10 ated in 18 patients (14 non-TCD, four TCD). Mixed
However, increasing levels of recipient cells over time chimaerism was an uncommon finding in recipients of (progressive mixed chimaerism) appear to predict relapse, unmanipulated BMT (21%) when compared to TCD especially in recipients of a T cell-depleted (TCD) trans-BMT (100%). No evidence of MRD, as identified using plant for CML.
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the BCR-ABL mRNA RT-PCR assay, was detected in At present, PCR amplification of a DNA polymorphism those patients who were donor chimaeras. Early and is one of the most sensitive methods for the detection of a transient MC and MRD was detected in four patients minor clone of recipient cells post-BMT. 5 Microsatellite or (two non-TCD, two TCD) who have subsequently conshort tandem repeat (STR) regions are widespread throughverted to a donor profile. One patient has stable lowout the human genome. These di-, tri-or tetra-nucleotide level MC but remains MRD negative 4 years post-BMT.
repeat sequences can vary in length between individuals Late MC and MRD was observed in two patients who and amplification of the polymorphic STRs (STR-PCR) has relapsed Ͼ6 years after TCD BMT for CML. We conbeen successfully used to monitor engraftment and chimaclude that mixed chimaerism is a rare event in recipieric status of patients following allogeneic BMT.
ents of unmanipulated BMT and that donor chimaerism
The persistence of leukaemic cells post-BMT is known as detected by STR-PCR assay is consistant with disas minimal resiudal disease (MRD). Patients with CML ease-free survival and identifies patients with a low risk exhibit a non-random chromosomal translocation called the236 Patients and methods temperature from 1 to 10 years using a standard SDS/proteinase K digestion. 26 Pretransplant recipient and Patients donor DNA samples were amplified to identify an informative polymorphism using a panel of STR markers. The Twenty-two patients who were transplanted for chronic STR-PCR protocol was as previously described. 10, 26 phase CML were entered into the study. All patients Briefly, 20-50 ng of DNA was added to a reaction mix received an HLA-identical sibling donor transplant in St containing 10 mM Tris-HCl pH 8.9, 50 mM KCl, 1% Triton James's Hospital from 1984 to 1993 and were in complete ×100, 1.5 mM MgCl 2 , 25 pM of each primer, 200 mol of clinical remission and at least 6 months post-BMT at the dATP, dGTP, dTTP and 2 mol dCTP. Samples were beginning of this study. Clinical characteristics of the given a 'hot start' of 5 min at 94°C, before adding 1 U of patient group are outlined in Table 1 . Conditioning conTaq polymerase (Perkin Elmer, Warrington, UK) and 1 Ci sisted of cyclophosphamide (60 mg/kg on 2 consecutive ␣ 32 P-dCTP and 4000 Ci/mmol (Amersham, Little Chalfont, days) in combination with either single fraction (7.5 Gy) UK). PCR amplification had the following cycling paratotal body irradiation (TBI) (n = 13), or busulphan (4 mg/kg meters: 94°C, 1 min; 55°C, 1 min; 72°C, 1 min for 30 for 4 days) (n = 9). As graft-versus-host disease (GVHD) cycles, with a final extension step of 72°C for 3 min. To prophylaxis, patients received cyclosporine (CYA) alone identify the possibility of operator contamination, operator (n = 8) or cyclosporine in combination with methotrexate DNA was included in each experiment. Following amplifi-(CYA and MTX) (n = 14). As additional GVHD prophycation, samples were electrophoresed on an 8% denaturing laxis five patients received a T cell-depleted bone marrow polyacrylamide sequencing gel and results were analysed infusion. Donor marrow was obtained with informed conafter exposing gels to autoradiography for 4, 12 and 24 h. sent on the day of transplant. Bone marrow aspirates were
The STR-PCR assay allows the detection of a minor cell taken at 3, 6 and 12 months post-BMT and thereafter yearly population at the 0.1-0.01% level. 26 Dilution experiments for morphological cytogenetic and molecular analysis.
were performed to ascertain the levels of recipient cells in Two patients (UPN011/86 and UPN006/88) received MC samples. The occurrence of MC and the percentage of donor leukocyte infusions (DLI) for relapsed CML, 6 and recipient cells was confirmed using a second informative 6.5 years post-T cell-depleted BMT. UPN 011/86 received STR marker. a total dose of 2.8 × 10 8 donor T cells/kg and UPN 006/88 received 2.9 × 10 8 donor T cells/kg. 5 × 10 6 U/m 2 interferon ␣ was given until days 50 and 64 post-first infusion, Cytogenetic analysis respectively.
Bone marrow aspirates were performed at varying intervals post-BMT. Karyotyping was performed using standard Short tandem repeat PCR techniques. A minimum of 25 metaphases was analysed per sample. This allows the detection of a minor clone at the DNA was extracted from fresh bone marrow mononuclear cells and from BM smears that had been stored at room 5% level.
RT-PCR analysis
006/92). UPN 003/91 had recipient cells present at 3 months post-BMT but was fully donor at 6 months and RNA was extracted from frozen BM and PB samples folon all subsequent analyses. UPN 005/91 showed low-level lowing red cell lysis using the Chomczynski method. 27 mixed chimaerism at all times post-BMT. At 1 year postWhere cell pellets were less than 1 × 10 6 cells, 2 g of gly-BMT, 10% recipient cells were present. Low levels of Ͻ5% cogen (Boehringer Mannheim, Lewes, UK) was added as recipient cells persist to the last follow-up sample at 4 years an RNA carrier. Two micrograms of RNA were treated post-BMT. UPN 006/92 showed evidence of recipient cells with DNAse I (Gibco BRL, Paisley, UK) and reverse tranup to 2 years post-BMT. The levels of recipient cells scribed using MMLV reverse transcriptase (Gibco BRL, decreased with time and analysis at 3 years post-BMT Paisley, UK) following the manufacturer's recommenshowed an exclusively donor profile. dations. Strict contamination avoidance procedures were Four of four patients studied who received a T cellfollowed and control reactions were added at each stage depleted BMT exhibited MC (007/86, 011/86, 005/88, of the RNA procedure. Two-step nested PCR analysis was 006/88). UPN 007/86 had evidence of recipient cells within performed using the protocol described by Roth et al. 16, 19 the first year post-BMT but exhibited a donor profile on The amplification protocol was adapted to accommodate subsequent analyses. UPN 005/88 showed a mixed chimathe use of dUTP in place of dTTP (PCR Carryover Preveneric profile at 1 and 3 years post-BMT. Analysis from 4 to tion Kit; Perkin Elmer). The incorporation of uracil into the 7 years post-BMT demonstrated a donor profile. UPN PCR reaction products (amplicons) enables all subsequent 011/86 was a mixed chimaera with 5% recipient cells primary and nested PCR mixes to be treated with uracildetected at 5 years post-BMT, 1 year prior to haematologic N-glycosylase (UNG) which will cleave any contaminating relapse. Subsequent chimaerism analysis at the time of amplicons. 28 The UNG is subsequently denatured at 94°C relapse indicated the presence of Ͼ95% recipient cells. for 3 min, before adding cDNA. The use of the PCR carry-UPN 006/88 had not been assessed for chimaeric status over prevention kit successfully eliminated any further false prior to relapse but Ͼ95% recipient cells were detected at positive results.
time of full haematological relapse. Donor leukocyte The PCR products were visualised on ethidium bromideinfusions resulted in the elimination of the recipient cells stained 2% agarose gels. The product of the b3a2 transcript and the establishment of a complete donor chimaeric profile is 300 bp in size and the b2a2 transcript gives rise to a by day 91 post first infusion in both patients. , 1 year postEighteen of the 22 patients were studied from 6 months to BMT and remained PCR negative on all subsequent analy-10 years post-BMT. Chimaeric assessment was not possible ses. This group included 13/15 patients who received an in four patients as no pretransplant and/or donor material unmanipulated BMT. was available for analysis. A median of five analyses (range 2-6) was performed for each patient post-BMT (Figure 1 BCR-ABL mRNA positive: Early BCR-ABL positivity was and Table 2 Figure 1 and RT-PCR negative. Two T cell-depleted BMT recipients Table 2 ). These patients all received an unmanipulated relapsed; UPN 011/86 had a PCR positive result 10 months BMT, thus donor chimaerism was observed in 78% (11/14) prior to haematological relapse. UPN 006/88 was negative of patients receiving an unmanipulated BMT while 0/4 2 years before haematological relapse, but no subsequent recipients of T cell-depleted transplants exhibited a comsample was available for analysis. Analysis at 6 months plete donor profile at all times tested (Table 2) .
post-DLI therapy indicated that the leukaemic clone had been eliminated. Figure 1 and Years post-BMT dence of MC, 3/12 patients (25%), is similar to our own DC = donor chimaerism; MC = mixed chimaerism; HR = haematological study. Thus the incidence of MC following unmanipulated relapse; CyR = cytogenetic relapse; DF = disease free.
BMT for CP-CML is approximately 20% and this is substantially lower than the 50-100% incidence report by different studies following T cell-depleted BMT for CML. However, of these four patients, two subsequently progressed to haematological relapse while two remain BCR-ABL positive and presumably at risk of relapse. UPN 005/91 and UPN 5/88 remain Ph and BCR-ABL negative 3 Discussion and 4 years post-transient cytogenetic relapse, respectively, without clinical intervention. Two patients (UPNs 0011/86 Chimaeric studies in patients undergoing BMT for CML have indicated that MC is a common event but the majority and 006/88) relapsed 6.5 and 6 years following TCD BMT for CML. Both patients had predominantly recipient of studies have involved T cell-depleted BMT recipients. 5 None the less, these results have indicated a putative associhaemopoiesis and were BCR-ABL positive at time of relapse. They responded to donor lymphocyte infusions ation between MC, the presence of MRD and risk of leukaemia relapse.
7-9, 14 Roux et al 29 found that 7/8 (87%) of (DLI) and remain in full haematological and molecular recourse to technically difficult quantitative PCR assays.
